Abstract：Objective: To analyze the correlation between levels of C1q tumor necrosis factor-related protein 3 (CTRP-3) and C1q tumor necrosis factor-related protein 12 (CTRP12) and global initiative (GOLD) grading and prognosis of chronic obstructive pulmonary disease (COPD). Methods: A total of 126 patients with COPD in the hospital were selected from September 2022 to January 2024 and included in the case group, and 90 healthy volunteers receiving physical examination were assigned into the control group. The clinical data and serum CTRP-3 and CTRP12 levels were compared between both groups. According to the GOLD grading, COPD patients were classified into grade I group (n=9), grade Ⅱ group (n=21), grade Ⅲ group (n=43) and grade IV group (n=53). The levels of CTRP-3 and CTRP12 among the four groups were compared. The prognosis in the case group was recorded, and the CTRP-3 and CTRP12 levels were compared among patients with different prognosis status. Pearson correlation analysis was adopted to explore the correlation between clinical indicators and levels of serum CTRP-3 and CTRP12. Results: The age, gender, body mass index, smoking history and underlying diseases between the two groups manifested no statistical differences (P>0.05). WBC in the case group was higher (P<0.05) while FEV1 and FEV1/FVC were lower than those in the control group (P<0.05). The levels of CTRP-3 and CTRP12 were lower in the case group (P<0.05). There were statistical differences in the levels of CTRP-3 and CTRP12 among COPD patients with different GOLD grades (P<0.05). CTRP-3 and CTRP12 levels were manifested as grade I group>grade Ⅱ group>grade Ⅲ group>grade IV group (P<0.05). Compared with the poor prognosis group, the levels of CTRP-3 and CTRP12 in the good prognosis group were higher (P<0.05). Correlation analysis showed that serum CTRP-3 level in COPD patients was negatively correlated with smoking history and GOLD grading (P<0.05), and was positively associated with FEV1/FVC (P<0.05). CTRP12 level was negatively correlated with smoking history, WBC and GOLD grading (P<0.05), and was positively correlated with FEV1/FVC (P<0.05). The levels of CTRP-3 and CTRP12 were not correlated with the duration of COPD, hospital stay and FEV1 (P>0.05). Conclusion: Serum levels of CTRP-3 and CTRP12 in COPD patients are lower compared with those of healthy people, and are negatively correlated with smoking history and GOLD grading, and positively correlated with FEV1/FVC level.
[1] Turner E,E Jenks M.Cost-effectiveness analysis of the use of high-flow oxygen through nasal cannula in intensive care units in NHS England[J].Expert Rev Pharmacoecon Outcomes Res,2018,18(4):331-337. [2] A P M D,A W J,B M M.Chronic obstructive pulmonary disease.[J].Lancet (London,England),2020,379(9823):1341-1351. [3] Fan Y,Xu W,Wang Y,et al.Association of occupational dust exposure with combined chronic obstructive pulmonary disease and pneumoconiosis: a cross-sectional study in China.[J].BMJ open,2020,10(9):38874. [4] Park H Y,Kang D,Shin S H,et al.Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study[J].Thorax,2020,75(6):506-509. [5] 唐春冬,周文武,张芝云,等.COPD患者血清炎症细胞因子水平与肺动脉压力的相关性[J].国际呼吸杂志,2022,42(18):1376-1381. [6] Chen,Xinpan,Yiru,et al.C1q/tumor necrosis factor-related protein-3 improves renal fibrosis via inhibiting notch signaling pathways[J].J cell physiol.2019,234(12):22352-22364. [7] 陈艳蓉,石赟,王珊,等.老年慢性阻塞性肺疾病急性加重期患者血清CTRP-4,CTRP-6,CTRP-9与肺功能和炎症因子的相关性分析[J].现代生物医学进展,2023,23(10):1857-1861. [8] 中国康复医学会循证康复医学工作委员会,中国康复研究中心/中国康复科学所康复信息研究所,兰州大学循证医学中心,等.慢性阻塞性肺疾病临床康复循证实践指南[J].中国康复理论与实践 2021,27(1):15-26. [9] 纵单单,陈平.慢性阻塞性肺疾病防治全球倡议2017更新要点解读[J].中华结核和呼吸杂志,2017,40(5):380-385. [10] 王莹,陈卫东,刘磊.糖尿病肾病患者血清C1q/肿瘤坏死因子相关蛋白3的表达及临床意义[J].国际泌尿系统杂志,2021,41(1):129-134. [11] 熊思明,叶仁群.芪丹颗粒对2型糖尿病患者胰岛素抵抗及血清CTRP6和CTRP12水平的影响[J].广州中医药大学学报,2020,37(12):2286-2292. [12] 张海霞,田海燕,倪晓琴.慢性阻塞性肺病并发肺心病患者急性糖代谢异常的原因分析与护理干预[J].贵州医药,2022,46(5):833-834. [13] 朱丹,陈慧,杨锡光,等.外周血WBC,C反应蛋白及纤维蛋白原与慢性阻塞性肺疾病急性加重风险的相关性分析[J].浙江医学,2019,41(14):1522-1524. [14] Dan X,Jian L,Cardiology D O.Function of CTRP3 in glucolipid metabolism and cardiovascular protection[J].Advances in Cardiovascular Diseases,2018,39(3):435-437.
2024, Vol. 30 
冀公网安备13080202000786号